Full Text Journal Articles in
Journal Lancet Neurol

Advertisement

Find full text journal articles






Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, ,

<h4>Background</h4>Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.<h4>Methods</h4>We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):182-192]

Cited: 0 times

View full text PDF listing >>



An extraordinary World Encephalitis Day.

Ava Easton, Benedict D Michael,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):172]

Cited: 0 times

View full text PDF listing >>



Advertisement

RT-QuIC for detection of prodromal α-synucleinopathies.

Inga Zerr,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):165-166]

Cited: 0 times

View full text PDF listing >>



New insights into atypical Alzheimer's disease in the era of biomarkers.

Jonathan Graff-Radford, Keir X X Yong, Liana G Apostolova, Femke H Bouwman, Maria Carrillo, Bradford C Dickerson, Gil D Rabinovici, Jonathan M Schott, David T Jones, Melissa E Murray,

Most patients with Alzheimer's disease present with amnestic problems; however, a substantial proportion, over-represented in young-onset cases, have atypical phenotypes including predominant visual, language, executive, behavioural, or motor dysfunction. In the past, these individuals often received a late diagnosis; however, availability of CSF and PET biomarkers of Alzheimer's disease pathologies ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):222-234]

Cited: 0 times

View full text PDF listing >>



Nicolien van der Kolk.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):174]

Cited: 0 times

View full text PDF listing >>



Advanced consent for acute stroke trials - Authors' reply.

Jeroen T J M van Dijck, Erwin J O Kompanje, Paul J Nederkoorn, Wilco C Peul, Diederik W J Dippel,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):170-171]

Cited: 0 times

View full text PDF listing >>



Lessons learned from a progressive supranuclear palsy trial.

Murray Grossman,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):162-163]

Cited: 0 times

View full text PDF listing >>



Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Peter Hermann, Brian Appleby, Jean-Philippe Brandel, Byron Caughey, Steven Collins, Michael D Geschwind, Alison Green, Stephane Haïk, Gabor G Kovacs, Anna Ladogana, Franc Llorens, Simon Mead, Noriyuki Nishida, Suvankar Pal, Piero Parchi, Maurizio Pocchiari, Katsuya Satoh, Gianluigi Zanusso, Inga Zerr,

Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused by misfolded prion proteins (PrP<sup>Sc</sup>). Effective therapeutics are currently not available and accurate diagnosis can be challenging. Clinical diagnostic criteria use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and EEG. Supportive biomarkers, such as high CSF total tau, ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):235-246]

Cited: 0 times

View full text PDF listing >>



The elementary sleep habits of Sherlock Holmes.

Alex Iranzo,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):179-180]

Cited: 0 times

View full text PDF listing >>



A WHO resolution on epilepsy and other neurological disorders.

Andrea Sylvia Winkler, Matilde Leonardi, Benedict Daniel Michael, Foad Abd-Allah, William Carroll, Alla Guekht, ,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):171-172]

Cited: 0 times

View full text PDF listing >>



Treatment of asymptomatic carotid stenosis.

J David Spence,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):163-165]

Cited: 0 times

View full text PDF listing >>



Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.

Alex Iranzo, Graham Fairfoul, Anutra Chumbala Na Ayudhaya, Monica Serradell, Ellen Gelpi, Isabel Vilaseca, Raquel Sanchez-Valle, Carles Gaig, Joan Santamaria, Eduard Tolosa, Renata L Riha, Alison J E Green,

<h4>Background</h4>Isolated rapid-eye-movement (REM) sleep behaviour disorder (IRBD) can be part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia with Lewy bodies. Real-time quaking-induced conversion (RT-QuIC) analysis of CSF has high sensitivity and specificity for the detection of misfolded α-synuclein in patients with Parkinson's disease and dementia with ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):203-212]

Cited: 0 times

View full text PDF listing >>



Cajal's illustrations inspire reparative acts.

Arpan Mehta,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):174]

Cited: 0 times

View full text PDF listing >>



Advanced consent for acute stroke trials.

Michel Shamy, Brian Dewar, Naomi Niznick, Stuart Nicholls, Dar Dowlatshahi,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):170]

Cited: 0 times

View full text PDF listing >>



Diversity and inclusion in clinical neurosciences.

The Lancet Neurology,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):161]

Cited: 0 times

View full text PDF listing >>



Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.

Dominic P J Howard, Liam Gaziano, Peter M Rothwell, ,

<h4>Background</h4>There is uncertainty around which patients with asymptomatic carotid stenosis should be offered surgical intervention. Although stroke rates were unrelated to the degree of stenosis in the medical-treatment-only groups in previous randomised trials, this could simply reflect recruitment bias and there has been no systematic analysis of a stenosis-risk association ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):193-202]

Cited: 0 times

View full text PDF listing >>



Lisa L Barnes: championing dementia research in minorities.

Priya Venkatesan,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):173]

Cited: 0 times

View full text PDF listing >>



Isolated bulbar palsy after SARS-CoV-2 infection.

Massimiliano Todisco, Enrico Alfonsi, Sebastiano Arceri, Giulia Bertino, Carlo Robotti, Michele Albergati, Matteo Gastaldi, Cristina Tassorelli, Giuseppe Cosentino,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):169-170]

Cited: 0 times

View full text PDF listing >>



Blood pressure management after endovascular therapy.

Wendy C Ziai, Mais Al-Kawaz,

Lancet Neurol (The Lancet. Neurology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.

Mikael Mazighi, Sebastien Richard, Bertrand Lapergue, Igor Sibon, Benjamin Gory, Jerome Berge, Arturo Consoli, Julien Labreuche, Jean-Marc Olivot, Joseph Broderick, Alain Duhamel, Emmanuel Touze, Adnan I Qureshi, Amélie Yavchitz, Simon Escalard, Jean-Philippe Desilles, Hocine Redjem, Stanislas Smajda, Robert Fahed, Solène Hébert, Benjamin Maïer, François Delvoye, Perrine Boursin, Malek Ben Maacha, Michael Obadia, Candice Sabben, Raphael Blanc, Julien Savatovsky, Michel Piotin, ,

<h4>Background</h4>High systolic blood pressure after successful endovascular therapy for acute ischaemic stroke is associated with increased risk of intraparenchymal haemorrhage. However, no randomised controlled trials are available to guide optimal management. We therefore aimed to assess whether an intensive systolic blood pressure target resulted in reduced rates of intraparenchymal haemorrhage ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Neurology 2021; 20: 235-46.

Lancet Neurol (The Lancet. Neurology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Menstrual migraine: a distinct disorder needing greater recognition.

Kjersti Grøtta Vetvik, E Anne MacGregor,

The term menstrual migraine refers to migraine that is associated with menstruation by more than chance, but it does not define pathophysiology. Menstrual migraine affects about 20-25% of female migraineurs in the general population, and 22-70% of patients presenting to headache clinics. In women diagnosed with menstrual migraine, perimenstrual migraine ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Neurology 2021; 19: 1033-42.

Lancet Neurol (The Lancet. Neurology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Neurol 2021; 20: 49-59.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):e2]

Cited: 0 times

View full text PDF listing >>



Dementia and COVID-19: a health and research funding crisis.

Liesbeth Aerts, Elsa Lauwers, Bart De Strooper,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):90]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.8922 s